Moreover, with the advent of the new WHO classification of brain tumors in 2021 [27], some different approaches to brain tumor nomenclature and grading have changed, and new molecular entities have been defined (e.g., IDH-mutant grade 4 astrocytoma and IDH-wild type molecularly defined glioblastoma), whose behavior in terms of prognosis and response to standardized treatment remains to be defined. Here, IDH1 is linked to astrocytoma (excluding glioblastoma).